{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T21:26:11Z","timestamp":1791494771311,"version":"4.3.4"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Crit Care"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The Tigris trial recently reported that polymyxin B hemoadsorption (PMX) achieved a high posterior probability of benefit for mortality in adults with endotoxic septic shock (endotoxemia with multiple organ failure). The trial used a Bayesian framework with a prior derived from a subgroup of an earlier trial (EUPHRATES) and this subgroup was used to design eligibility criteria for Tigris. Ten questions that expose the trial's strengths and limitations are answered in this review. Writing as the trial investigators, our intention is to make the reasoning behind these decisions explicit, so that clinicians and trialists can judge what Tigris does, and does not, demonstrate.<\/jats:p>","DOI":"10.1186\/s13054-026-06219-y","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T12:54:55Z","timestamp":1787835295000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Polymyxin B hemoadsorption in endotoxic septic shock: ten questions on the Tigris trial"],"prefix":"10.1186","volume":"30","author":[{"given":"Matthieu","family":"Legrand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Neyra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Tomlinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A","family":"Kellum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,27]]},"reference":[{"key":"6219_CR1","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1056\/NEJMoa1202290","volume":"366","author":"VM Ranieri","year":"2012","unstructured":"Ranieri VM, Thompson BT, Barie PS, Dhainaut J-F, Douglas IS, Finfer S, et al. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med. 2012;366:2055\u201364. https:\/\/doi.org\/10.1056\/NEJMoa1202290.","journal-title":"N Engl J Med"},{"key":"6219_CR2","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1159\/000315921","volume":"167","author":"DN Cruz","year":"2010","unstructured":"Cruz DN, de Cal M, Piccinni P, Ronco C. Polymyxin-B hemoperfusion and endotoxin removal: lessons from a review of the literature. Contrib Nephrol. 2010;167:77\u201382. https:\/\/doi.org\/10.1159\/000315921.","journal-title":"Contrib Nephrol."},{"key":"6219_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-023-04690-5","volume":"27","author":"JA Kellum","year":"2023","unstructured":"Kellum JA, Ronco C. The role of endotoxin in septic shock. Crit Care. 2023;27:400. https:\/\/doi.org\/10.1186\/s13054-023-04690-5.","journal-title":"Crit Care"},{"key":"6219_CR4","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1001\/jama.2009.856","volume":"301","author":"DN Cruz","year":"2009","unstructured":"Cruz DN, Antonelli M, Fumagalli R, Foltran F, Brienza N, Donati A, et al. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA. 2009;301:2445\u201352. https:\/\/doi.org\/10.1001\/jama.2009.856.","journal-title":"JAMA"},{"key":"6219_CR5","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1007\/s00134-015-3751-z","volume":"41","author":"DM Payen","year":"2015","unstructured":"Payen DM, Guilhot J, Launey Y, Lukaszewicz AC, Kaaki M, Veber B, et al. Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: a multicenter randomized control trial. Intensive Care Med. 2015;41:975\u201384. https:\/\/doi.org\/10.1007\/s00134-015-3751-z.","journal-title":"Intensive Care Med"},{"key":"6219_CR6","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1001\/jama.2018.14618","volume":"320","author":"RP Dellinger","year":"2018","unstructured":"Dellinger RP, Bagshaw SM, Antonelli M, Foster DM, Klein DJ, Marshall JC, et al. Effect of targeted polymyxin B hemoperfusion on 28-day mortality in patients with septic shock and elevated endotoxin level: the EUPHRATES randomized clinical trial. JAMA. 2018;320:1455\u201363. https:\/\/doi.org\/10.1001\/jama.2018.14618.","journal-title":"JAMA"},{"key":"6219_CR7","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1007\/s00134-018-5463-7","volume":"44","author":"DJ Klein","year":"2018","unstructured":"Klein DJ, Foster D, Walker PM, Bagshaw SM, Mekonnen H, Antonelli M. Polymyxin B hemoperfusion in endotoxemic septic shock patients without extreme endotoxemia: a post hoc analysis of the EUPHRATES trial. Intensive Care Med. 2018;44:2205\u201312. https:\/\/doi.org\/10.1007\/s00134-018-5463-7.","journal-title":"Intensive Care Med"},{"key":"6219_CR8","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/S2213-2600(26)00047-0","volume":"14","author":"JA Neyra","year":"2026","unstructured":"Neyra JA, Legrand M, Tidswell MA, Al-Khafaji A, Galphin C, Rains R, et al. Polymyxin B haemoadsorption in endotoxic septic shock (Tigris): a multicentre, open-label, Bayesian, randomised, controlled, phase 3 trial. Lancet Respir Med. 2026;14:443\u201352. https:\/\/doi.org\/10.1016\/S2213-2600(26)00047-0.","journal-title":"Lancet Respir Med"},{"key":"6219_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242216185","volume":"24","author":"DM Foster","year":"2023","unstructured":"Foster DM, Kellum JA. Endotoxic septic shock: diagnosis and treatment. Int J Mol Sci. 2023;24:16185. https:\/\/doi.org\/10.3390\/ijms242216185.","journal-title":"Int J Mol Sci"},{"key":"6219_CR10","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1056\/NEJMoa2100433","volume":"384","author":"AC Gordon","year":"2021","unstructured":"REMAP-CAP Investigators, Gordon AC, Mouncey PR, Al-Beidh F, Rowan KM, Nichol AD, et al. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. N Engl J Med. 2021;384:1491\u2013502. https:\/\/doi.org\/10.1056\/NEJMoa2100433.","journal-title":"N Engl J Med."},{"key":"6219_CR11","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1056\/NEJMoa2309995","volume":"389","author":"TE Hills","year":"2023","unstructured":"REMAP-CAP Investigators, Hills TE, Lorenzi E, Berry LR, Shyamsundar M, Al-Beidh F, et al. Simvastatin in Critically Ill Patients with Covid-19. N Engl J Med. 2023;389:2341\u201354. https:\/\/doi.org\/10.1056\/NEJMoa2309995.","journal-title":"N Engl J Med."},{"key":"6219_CR12","unstructured":"PANTHER. [cited 2026 July 9]. https:\/\/panthertrial.org. Accessed 9 July 2026"},{"key":"6219_CR13","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa2308440","volume":"390","author":"G Pradilla","year":"2024","unstructured":"Pradilla G, Ratcliff JJ, Hall AJ, Saville BR, Allen JW, Paulon G, et al. Trial of early minimally invasive removal of intracerebral hemorrhage. N Engl J Med. 2024;390:1277\u201389. https:\/\/doi.org\/10.1056\/NEJMoa2308440.","journal-title":"N Engl J Med"},{"key":"6219_CR14","unstructured":"Research C for DE and. Use of Bayesian Methodology in Clinical Trials of Drug and Biological Products. FDA; 2026 [cited 2026 May 26]. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/use-bayesian-methodology-clinical-trials-drug-and-biological-products. Accessed 26 May 2026"},{"key":"6219_CR15","unstructured":"Research C for DE and. Adjusting for Covariates in Randomized Clinical Trials for Drugs and Biological Products. FDA; 2024 [cited 2026 May 26]. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/adjusting-covariates-randomized-clinical-trials-drugs-and-biological-products. Accessed 26 May 2026"},{"key":"6219_CR16","unstructured":"Health C for D and R. Guidance for the Use of Bayesian Statistics in Medical Device Clinical Trials. FDA; 2020 [cited 2026 May 26]. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/guidance-use-bayesian-statistics-medical-device-clinical-trials. Accessed 26 May 2026"},{"key":"6219_CR17","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1164\/rccm.202310-1757VP","volume":"209","author":"EC Goligher","year":"2024","unstructured":"Goligher EC, Harhay MO. What is the point of Bayesian analysis? Am J Respir Crit Care Med. 2024;209:485\u20137. https:\/\/doi.org\/10.1164\/rccm.202310-1757VP.","journal-title":"Am J Respir Crit Care Med"},{"key":"6219_CR18","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/S0140-6736(24)01295-9","volume":"404","author":"EC Goligher","year":"2024","unstructured":"Goligher EC, Heath A, Harhay MO. Bayesian statistics for clinical research. Lancet. 2024;404:1067\u201376. https:\/\/doi.org\/10.1016\/S0140-6736(24)01295-9.","journal-title":"Lancet"},{"key":"6219_CR19","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1097\/CCM.0000000000005721","volume":"51","author":"JO Friedrich","year":"2023","unstructured":"Friedrich JO, Harhay MO, Angus DC, Burns KEA, Cook DJ, Fergusson DA, et al. Mortality as a measure of treatment effect in clinical trials recruiting critically ill patients. Crit Care Med. 2023;51:222\u201330. https:\/\/doi.org\/10.1097\/CCM.0000000000005721.","journal-title":"Crit Care Med"},{"key":"6219_CR20","doi-asserted-by":"publisher","unstructured":"National Heart, Lung, and Blood Institute Prevention and Early Treatment of Acute Lung Injury Clinical Trials Network, Shapiro NI, Douglas IS, Brower RG, Brown SM, Exline MC, et al. Early Restrictive or Liberal Fluid Management for Sepsis-Induced Hypotension. N Engl J Med. 2023;388:499\u2013510. https:\/\/doi.org\/10.1056\/NEJMoa2212663","DOI":"10.1056\/NEJMoa2212663"},{"key":"6219_CR21","doi-asserted-by":"publisher","unstructured":"ARISE FLUIDS Investigators, the ANZICS Clinical Trials Group, and the ACEM Clinical Trials Network, Peake SL, Macdonald SPJ, Howe BD, Milford E, Jones P, et al. Vasopressors or Fluids in Early Septic Shock. N Engl J Med. 2026. https:\/\/doi.org\/10.1056\/NEJMoa2516225","DOI":"10.1056\/NEJMoa2516225"},{"key":"6219_CR22","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1097\/CCM.0000000000005991","volume":"51","author":"J-J Chen","year":"2023","unstructured":"Chen J-J, Lai P-C, Lee T-H, Huang Y-T. Blood purification for adult patients with severe infection or sepsis\/septic shock: a network meta-analysis of randomized controlled trials. Crit Care Med. 2023;51:1777\u201389. https:\/\/doi.org\/10.1097\/CCM.0000000000005991.","journal-title":"Crit Care Med"},{"key":"6219_CR23","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-026-08361-1","author":"HC Prescott","year":"2026","unstructured":"Prescott HC, Antonelli M, Alhazzani W, M\u00f8ller MH, Alshamsi F, Azevedo LCP, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2026. Intensive Care Med. 2026. https:\/\/doi.org\/10.1007\/s00134-026-08361-1.","journal-title":"Intensive Care Med"}],"container-title":["Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13054-026-06219-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-026-06219-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-026-06219-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T10:11:39Z","timestamp":1791454299000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13054-026-06219-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,27]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6219"],"URL":"https:\/\/doi.org\/10.1186\/s13054-026-06219-y","relation":{},"ISSN":["1364-8535"],"issn-type":[{"value":"1364-8535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,27]]},"assertion":[{"value":"28 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable (debate article based on previously published trial data).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"ML, JAN, GT, JK are co-authors of the Tigris trial. Dr Legrand discloses grant support from the National Institutes of Health NIH (R01-GM151494-01 and NIH R01DK139484-01) and consulting fees from Idorsia, Vantive, Estor, OceaneX and is cofounder of Augura. Dr Neyra discloses grant support from the National Institutes of Health (R01DK128208, R01DK133539, U01DK12998, and U54DK137307) and consulting fees from Vantive, and CovarsaDx. Dr Tomlinson discloses fees from Spectral Medical for performing the statistical analysis. Dr Kellum discloses consulting fees paid by AstraZeneca, Bayer, bioM\u00e9rieux, Chugai Pharma, Mitsubishi Tenabe.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"519"}}